Luxbright AB
The answer first
Does Luxbright beat the market?
No, Luxbright has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 59% of Nordic stocks
- Quality62
- Value97
- Trend9
No. 51 of 195 in healthcare
Max for seven days
Follow Luxbright with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Luxbright
Your first answer is free, no account needed.
Do you own Luxbright, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Luxbright and a few more. Free, no card.
Super Stock+44.6%In short
- Luxbright has fallen 90.6% over the past year, including dividends.
- Overall, Luxbright ranks better than 59% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 96.6%. The price is 98.5% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 59% of Nordic stocks.
No. 51 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 101 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.19
- Asset turnoverSales divided by everything the company owns0.26
- Return on equityProfit divided by equity−91.9%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
High Low price: you pay little for what the company earns and owns.
No. 5 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.3
- P/SPrice divided by sales0.9
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 156 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−9.2%
- 6 months−66.2%
- 9 months−84.7%
- 12 months−90.6%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Luxbright
One fund we follow owns Luxbright. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Luxbright
Luxbright AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 11 employees.
Luxbright AB (publ), a technology company, develops, manufactures, and sells microfocus x-ray tubes and sources for industrial and non-destructive testing applications worldwide. It also provides Luxbright IX1, an integrated x-ray source product; Luxbright MF1, an integrated microfocus x-ray tubes; and custom-made x-ray tubes. Luxbright AB (publ) was incorporated in 2012 and is headquartered in Västra Frölunda, Sweden.


See the full analysis of Luxbright.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card